Factors influencing the clinical outcomes of intense pulsed light for meibomian gland dysfunction
To observe the clinical outcomes of intense pulsed light (IPL) for meibomian gland dysfunction (MGD) and identify its influencing factors.Forty-eight eyes of 48 patients with MGD were included. Subjects were followed up 5 times on day 1, day 15, day 30, day 45, and day 120, and underwent 3 sessions...
Saved in:
Published in | Medicine (Baltimore) Vol. 100; no. 49; p. e28166 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
Lippincott Williams & Wilkins
10.12.2021
|
Subjects | |
Online Access | Get full text |
ISSN | 0025-7974 1536-5964 1536-5964 |
DOI | 10.1097/MD.0000000000028166 |
Cover
Loading…
Abstract | To observe the clinical outcomes of intense pulsed light (IPL) for meibomian gland dysfunction (MGD) and identify its influencing factors.Forty-eight eyes of 48 patients with MGD were included. Subjects were followed up 5 times on day 1, day 15, day 30, day 45, and day 120, and underwent 3 sessions of the IPL treatment on day 1, day 15 and day 30. Gender, age, duration of MGD, time of video display terminal usage, and severity of MGD were recorded at baseline. At every visit, Ocular Surface Disease Index (OSDI), eyelid margin abnormality score, tear film breakup time, Schirmer I test (S ɪ t) and corneal fluorescein staining were recorded. The clinical parameters before and after 3 IPL treatments were compared. Univariate and multivariable logistic regression analyses were performed to explore influencing factors.Compared with baseline, the tear film breakup time was increased and the corneal fluorescein staining score and OSDI were significantly decreased on day 45 and day 120 (all P < .001). In univariate analysis, among the patients with a younger age (18-39 years), moderate MGD, higher baseline S ɪ t and higher baseline OSDI, the IPL treatment had a higher effective rate (P = .032, .004, .024, and .014 respectively). The MGD severity was strongly associated with effective IPL, and patients with moderate MGD had an OR of 22.454 compared with the severe MGD patients (OR = 22.454, 95% CI: 2.890-174.436, P = .003).IPL effectively improves clinical symptoms and some signs in MGD patients. Age, MGD severity, baseline S ɪ t and baseline OSDI are potential factors that may influence the clinical outcomes of IPL. MGD severity is an independent influencing factor. |
---|---|
AbstractList | To observe the clinical outcomes of intense pulsed light (IPL) for meibomian gland dysfunction (MGD) and identify its influencing factors.
Forty-eight eyes of 48 patients with MGD were included. Subjects were followed up 5 times on day 1, day 15, day 30, day 45, and day 120, and underwent 3 sessions of the IPL treatment on day 1, day 15 and day 30. Gender, age, duration of MGD, time of video display terminal usage, and severity of MGD were recorded at baseline. At every visit, Ocular Surface Disease Index (OSDI), eyelid margin abnormality score, tear film breakup time, Schirmer I test (S ɪ t) and corneal fluorescein staining were recorded. The clinical parameters before and after 3 IPL treatments were compared. Univariate and multivariable logistic regression analyses were performed to explore influencing factors.
Compared with baseline, the tear film breakup time was increased and the corneal fluorescein staining score and OSDI were significantly decreased on day 45 and day 120 (all
P
< .001). In univariate analysis, among the patients with a younger age (18–39 years), moderate MGD, higher baseline S ɪ t and higher baseline OSDI, the IPL treatment had a higher effective rate (
P
= .032, .004, .024, and .014 respectively). The MGD severity was strongly associated with effective IPL, and patients with moderate MGD had an OR of 22.454 compared with the severe MGD patients (OR = 22.454, 95% CI: 2.890-174.436,
P
= .003).
IPL effectively improves clinical symptoms and some signs in MGD patients. Age, MGD severity, baseline S ɪ t and baseline OSDI are potential factors that may influence the clinical outcomes of IPL. MGD severity is an independent influencing factor. To observe the clinical outcomes of intense pulsed light (IPL) for meibomian gland dysfunction (MGD) and identify its influencing factors.Forty-eight eyes of 48 patients with MGD were included. Subjects were followed up 5 times on day 1, day 15, day 30, day 45, and day 120, and underwent 3 sessions of the IPL treatment on day 1, day 15 and day 30. Gender, age, duration of MGD, time of video display terminal usage, and severity of MGD were recorded at baseline. At every visit, Ocular Surface Disease Index (OSDI), eyelid margin abnormality score, tear film breakup time, Schirmer I test (S ɪ t) and corneal fluorescein staining were recorded. The clinical parameters before and after 3 IPL treatments were compared. Univariate and multivariable logistic regression analyses were performed to explore influencing factors.Compared with baseline, the tear film breakup time was increased and the corneal fluorescein staining score and OSDI were significantly decreased on day 45 and day 120 (all P < .001). In univariate analysis, among the patients with a younger age (18-39 years), moderate MGD, higher baseline S ɪ t and higher baseline OSDI, the IPL treatment had a higher effective rate (P = .032, .004, .024, and .014 respectively). The MGD severity was strongly associated with effective IPL, and patients with moderate MGD had an OR of 22.454 compared with the severe MGD patients (OR = 22.454, 95% CI: 2.890-174.436, P = .003).IPL effectively improves clinical symptoms and some signs in MGD patients. Age, MGD severity, baseline S ɪ t and baseline OSDI are potential factors that may influence the clinical outcomes of IPL. MGD severity is an independent influencing factor. To observe the clinical outcomes of intense pulsed light (IPL) for meibomian gland dysfunction (MGD) and identify its influencing factors.Forty-eight eyes of 48 patients with MGD were included. Subjects were followed up 5 times on day 1, day 15, day 30, day 45, and day 120, and underwent 3 sessions of the IPL treatment on day 1, day 15 and day 30. Gender, age, duration of MGD, time of video display terminal usage, and severity of MGD were recorded at baseline. At every visit, Ocular Surface Disease Index (OSDI), eyelid margin abnormality score, tear film breakup time, Schirmer I test (S ɪ t) and corneal fluorescein staining were recorded. The clinical parameters before and after 3 IPL treatments were compared. Univariate and multivariable logistic regression analyses were performed to explore influencing factors.Compared with baseline, the tear film breakup time was increased and the corneal fluorescein staining score and OSDI were significantly decreased on day 45 and day 120 (all P < .001). In univariate analysis, among the patients with a younger age (18-39 years), moderate MGD, higher baseline S ɪ t and higher baseline OSDI, the IPL treatment had a higher effective rate (P = .032, .004, .024, and .014 respectively). The MGD severity was strongly associated with effective IPL, and patients with moderate MGD had an OR of 22.454 compared with the severe MGD patients (OR = 22.454, 95% CI: 2.890-174.436, P = .003).IPL effectively improves clinical symptoms and some signs in MGD patients. Age, MGD severity, baseline S ɪ t and baseline OSDI are potential factors that may influence the clinical outcomes of IPL. MGD severity is an independent influencing factor.ABSTRACTTo observe the clinical outcomes of intense pulsed light (IPL) for meibomian gland dysfunction (MGD) and identify its influencing factors.Forty-eight eyes of 48 patients with MGD were included. Subjects were followed up 5 times on day 1, day 15, day 30, day 45, and day 120, and underwent 3 sessions of the IPL treatment on day 1, day 15 and day 30. Gender, age, duration of MGD, time of video display terminal usage, and severity of MGD were recorded at baseline. At every visit, Ocular Surface Disease Index (OSDI), eyelid margin abnormality score, tear film breakup time, Schirmer I test (S ɪ t) and corneal fluorescein staining were recorded. The clinical parameters before and after 3 IPL treatments were compared. Univariate and multivariable logistic regression analyses were performed to explore influencing factors.Compared with baseline, the tear film breakup time was increased and the corneal fluorescein staining score and OSDI were significantly decreased on day 45 and day 120 (all P < .001). In univariate analysis, among the patients with a younger age (18-39 years), moderate MGD, higher baseline S ɪ t and higher baseline OSDI, the IPL treatment had a higher effective rate (P = .032, .004, .024, and .014 respectively). The MGD severity was strongly associated with effective IPL, and patients with moderate MGD had an OR of 22.454 compared with the severe MGD patients (OR = 22.454, 95% CI: 2.890-174.436, P = .003).IPL effectively improves clinical symptoms and some signs in MGD patients. Age, MGD severity, baseline S ɪ t and baseline OSDI are potential factors that may influence the clinical outcomes of IPL. MGD severity is an independent influencing factor. |
Author | Chou, Yu-yu Long, Qin Chen, Chen Chen, Di |
AuthorAffiliation | a Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China b Key Laboratory of Ocular Fundus Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China |
AuthorAffiliation_xml | – name: a Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China – name: b Key Laboratory of Ocular Fundus Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China |
Author_xml | – sequence: 1 givenname: Chen surname: Chen fullname: Chen, Chen organization: Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China – sequence: 2 givenname: Di surname: Chen fullname: Chen, Di organization: Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China – sequence: 3 givenname: Yu-yu surname: Chou fullname: Chou, Yu-yu organization: Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China – sequence: 4 givenname: Qin surname: Long fullname: Long, Qin organization: Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34889288$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kU9vFSEUxYmpsa9PP4GJYelmKjDAwMbEtFZN2rjRNeExl_dQBp4D06bfXupr_dOFsCC5_M45ufeeoKOUEyD0kpJTSvTw5ur8lPw5TFEpn6AVFb3shJb8CK1aVXSDHvgxOinlGyG0Hxh_ho57rpRmSq2QvbCu5rngkHxcILmQtrjuALsYUnA24rxUlycoOPsGVUgF8H6JBUYcw3ZXsc8zniBs8hRswtto04jH2-KX5GrI6Tl66m3DX9y_a_T14v2Xs4_d5ecPn87eXXaOC6I7paXkXEtQ1veDFV5xSwUjG6KVI3YcnaJWMMHB98CAcqno4NXAhdVec9Gv0duD737ZTDA6SHW20eznMNn51mQbzL8_KezMNl8bJWWv2l2j1_cGc_6xQKlmCsVBbA1BXophkijBaYtq6Ku_s36HPMy1AfoAuDmXMoM3LlR7N44WHaKhxNzt0Fydm8c7bNr-kfbB_v8qflDd5FhhLt_jcgOz2YGNdfcLF4NmHSOMUkYJ6VpF6v4ngJ2vAA |
CitedBy_id | crossref_primary_10_1097_ICO_0000000000003837 crossref_primary_10_3390_jcm11164724 crossref_primary_10_1111_aos_15759 crossref_primary_10_1136_bmjopen_2023_078727 crossref_primary_10_1080_02713683_2022_2147955 crossref_primary_10_1097_ICU_0000000000001055 crossref_primary_10_21518_ms2023_485 crossref_primary_10_3390_jcm13216341 crossref_primary_10_1186_s12886_023_02939_9 |
Cites_doi | 10.1167/iovs.14-15764 10.1167/iovs.13-11914 10.1080/02713683.2017.1406525 10.1016/j.survophthal.2019.08.007 10.1016/j.ajo.2019.02.024 10.1097/MD.0000000000016547 10.1186/s12886-019-1219-6 10.1097/ICL.0000000000000236 10.1097/ICL.0000000000000704 10.1167/iovs.17-23651 10.1016/j.jtos.2017.05.001 10.1016/j.jtos.2020.01.003 10.1007/s10792-017-0633-0 10.1167/iovs.10-6997g 10.1089/pho.2017.4402 10.1167/iovs.10-6997a 10.1177/1120672118817687 10.1111/cxo.13035 10.1167/iovs.10-6997c 10.1167/iovs.10-6997e 10.1111/cxo.12541 10.1089/pho.2014.3819 10.4103/ijo.IJO_698_17 10.1371/journal.pone.0105575 10.1016/j.jtos.2018.11.004 10.1167/iovs.10-6997f 10.1097/ICO.0000000000000735 10.3390/diagnostics9040147 10.2147/OPTO.S217639 10.1155/2016/1910694 10.1186/s12886-020-01357-5 10.1097/ICO.0000000000002217 10.1097/ICO.0000000000000563 10.1111/aos.14651 10.1016/j.clae.2017.05.003 10.1097/ICL.0000000000000294 |
ContentType | Journal Article |
Copyright | Lippincott Williams & Wilkins Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. 2021 |
Copyright_xml | – notice: Lippincott Williams & Wilkins – notice: Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. – notice: Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. 2021 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1097/MD.0000000000028166 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1536-5964 |
EndPage | e28166 |
ExternalDocumentID | PMC8663838 34889288 10_1097_MD_0000000000028166 00005792-202112100-00069 |
Genre | Journal Article |
GrantInformation_xml | – fundername: the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences grantid: 2018PT32029 – fundername: the National Natural Science Foundation of China grantid: 81870685 – fundername: the Beijing Natural Science Foundation grantid: 7172173 |
GroupedDBID | --- .-D .XZ .Z2 01R 0R~ 354 40H 4Q1 4Q2 4Q3 5GY 5RE 5VS 71W 77Y 7O~ AAAAV AAGIX AAHPQ AAIQE AAMOA AAQKA AARTV AASCR AAWTL AAXQO AAYEP ABASU ABBUW ABCQX ABDIG ABFRF ABOCM ABVCZ ABXVJ ABZAD ABZZY ACDDN ACEWG ACGFO ACGFS ACILI ACLDA ACWDW ACWRI ACXJB ACXNZ ACZKN ADGGA ADHPY ADNKB ADPDF AE6 AEFWE AENEX AFBFQ AFDTB AGOPY AHOMT AHQNM AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC BQLVK CS3 DIWNM DU5 E.X EBS EEVPB ERAAH EX3 F2K F2L F2M F2N F5P FCALG FD6 FIJ FL- GNXGY GQDEL GROUPED_DOAJ H0~ HLJTE HYE HZ~ H~9 IKREB IKYAY IN~ IPNFZ JK3 JK8 K8S KD2 KMI KQ8 L-C N9A N~7 N~B O9- OAG OAH OB2 OHH OK1 OL1 OLB OLG OLH OLU OLV OLY OLZ OPUJH OUVQU OVD OVDNE OVEED OVIDH OVLEI OWV OWW OWZ OXXIT P2P RIG RLZ RPM RXW S4R S4S TAF TEORI TSPGW UNMZH V2I VVN W3M WOQ WOW X3V X3W XYM YFH YOC ZFV ZY1 AAYXX ADSXY CITATION 8L- ACIJW AWKKM CGR CUY CVF ECM EIF NPM ODA 7X8 5PM |
ID | FETCH-LOGICAL-c4509-89664496e8af37a5f84a1520b098c0addc81a5254ef3e2e146817f8745a9f9453 |
ISSN | 0025-7974 1536-5964 |
IngestDate | Thu Aug 21 18:45:17 EDT 2025 Tue Aug 05 10:00:08 EDT 2025 Wed Feb 19 02:24:45 EST 2025 Tue Aug 05 11:57:20 EDT 2025 Thu Apr 24 23:10:01 EDT 2025 Fri May 16 03:50:36 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 49 |
Language | English |
License | Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c4509-89664496e8af37a5f84a1520b098c0addc81a5254ef3e2e146817f8745a9f9453 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-8532-0999 |
OpenAccessLink | http://dx.doi.org/10.1097/MD.0000000000028166 |
PMID | 34889288 |
PQID | 2608541453 |
PQPubID | 23479 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8663838 proquest_miscellaneous_2608541453 pubmed_primary_34889288 crossref_citationtrail_10_1097_MD_0000000000028166 crossref_primary_10_1097_MD_0000000000028166 wolterskluwer_health_00005792-202112100-00069 |
PublicationCentury | 2000 |
PublicationDate | 20211210 2021-12-10 2021-Dec-10 |
PublicationDateYYYYMMDD | 2021-12-10 |
PublicationDate_xml | – month: 12 year: 2021 text: 20211210 day: 10 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Hagerstown, MD |
PublicationTitle | Medicine (Baltimore) |
PublicationTitleAlternate | Medicine (Baltimore) |
PublicationYear | 2021 |
Publisher | Lippincott Williams & Wilkins |
Publisher_xml | – name: Lippincott Williams & Wilkins |
References | Arita (R5-20250504) 2020; 103 Pinto-Fraga (R20-20250504) 2017; 43 Geerling (R38-20250504) 2011; 52 Craig (R7-20250504) 2015; 56 Albietz (R36-20250504) 2018; 101 Fu (R15-20250504) 2019; 98 Schaumberg (R1-20250504) 2011; 52 Yin (R34-20250504) 2018; 43 Yamaguchi (R32-20250504) 2018; 59 Arita (R22-20250504) 2019; 17 Chan (R3-20250504) 2019; 25 Rong (R8-20250504) 2018; 36 Tang (R25-20250504) 2020; 47 Giannaccare (R31-20250504) 2019; 11 Vegunta (R10-20250504) 2016; 35 Xue (R30-20250504) 2020; 18 Karaca (R24-20250504) 2020; 30 Huang (R19-20250504) 2019; 19 Titiyal (R23-20250504) 2018; 66 Wolffsohn (R16-20250504) 2017; 15 Wu (R12-20250504) 2014; 9 Villani (R27-20250504) 2013; 54 Nichols (R17-20250504) 2011; 52 Toyos (R35-20250504) 2015; 33 Hashemi (R37-20250504) 2017; 40 Sabeti (R4-20250504) 2020; 65 Jiang (R13-20250504) 2016; 2016 Knop (R26-20250504) 2011; 52 Vigo (R33-20250504) 2019; 9 Na (R21-20250504) 2021; 99 Kuriakose (R28-20250504) 2018; 38 Chatterjee (R2-20250504) 2020; 39 Liang (R29-20250504) 2015; 34 Tomlinson (R6-20250504) 2011; 52 Paugh (R14-20250504) 2018; 44 Ge (R18-20250504) 2020; 20 Arita (R11-20250504) 2019; 207 |
References_xml | – volume: 56 start-page: 1965 year: 2015 ident: R7-20250504 article-title: Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.14-15764 – volume: 54 start-page: 4735 year: 2013 ident: R27-20250504 article-title: The aging Meibomian gland: an in vivo confocal study publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.13-11914 – volume: 43 start-page: 308 year: 2018 ident: R34-20250504 article-title: Changes in the meibomian gland after exposure to intense pulsed light in meibomian gland dysfunction (MGD) patients publication-title: Curr Eye Res doi: 10.1080/02713683.2017.1406525 – volume: 65 start-page: 205 year: 2020 ident: R4-20250504 article-title: Management of meibomian gland dysfunction: a review publication-title: Surv Ophthalmol doi: 10.1016/j.survophthal.2019.08.007 – volume: 207 start-page: 410 year: 2019 ident: R11-20250504 article-title: Meibomian gland dysfunction and dry eye are similar but different based on a population-based study: the hirado-takushima study in Japan publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2019.02.024 – volume: 98 start-page: e16547 year: 2019 ident: R15-20250504 article-title: Evaluation of ocular surface impairment in meibomian gland dysfunction of varying severity using a comprehensive grading scale publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000016547 – volume: 19 start-page: 211 year: 2019 ident: R19-20250504 article-title: Clinical results of intraductal meibomian gland probing combined with intense pulsed light in treating patients with refractory obstructive meibomian gland dysfunction: a randomized controlled trial publication-title: BMC Ophthalmol doi: 10.1186/s12886-019-1219-6 – volume: 43 start-page: 57 year: 2017 ident: R20-20250504 article-title: Efficacy and safety of 0.2% hyaluronic acid in the management of dry eye disease publication-title: Eye Contact Lens doi: 10.1097/ICL.0000000000000236 – volume: 47 start-page: 38 year: 2020 ident: R25-20250504 article-title: A retrospective study of treatment outcomes and prognostic factors of intense pulsed light therapy combined with meibomian gland expression in patients with meibomian gland dysfunction publication-title: Eye Contact Lens doi: 10.1097/ICL.0000000000000704 – volume: 59 start-page: DES192 year: 2018 ident: R32-20250504 article-title: Inflammatory response in dry eye publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.17-23651 – volume: 25 start-page: 38 year: 2019 ident: R3-20250504 article-title: Update on the association between dry eye disease and meibomian gland dysfunction publication-title: Hong Kong Med J – volume: 15 start-page: 539 year: 2017 ident: R16-20250504 article-title: TFOS DEWS II diagnostic methodology report publication-title: Ocul Surf doi: 10.1016/j.jtos.2017.05.001 – volume: 18 start-page: 286 year: 2020 ident: R30-20250504 article-title: Randomised double-masked placebo-controlled trial of the cumulative treatment efficacy profile of intense pulsed light therapy for meibomian gland dysfunction publication-title: Ocul Surf doi: 10.1016/j.jtos.2020.01.003 – volume: 38 start-page: 1809 year: 2018 ident: R28-20250504 article-title: Dyslipidemia and its association with meibomian gland dysfunction: a systematic review publication-title: Int Ophthalmol doi: 10.1007/s10792-017-0633-0 – volume: 52 start-page: 2050 year: 2011 ident: R38-20250504 article-title: The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.10-6997g – volume: 36 start-page: 326 year: 2018 ident: R8-20250504 article-title: Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction publication-title: Photomed Laser Surg doi: 10.1089/pho.2017.4402 – volume: 52 start-page: 1922 year: 2011 ident: R17-20250504 article-title: The international workshop on meibomian gland dysfunction: executive summary publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.10-6997a – volume: 30 start-page: 289 year: 2020 ident: R24-20250504 article-title: Intense regulated pulse light for the meibomian gland dysfunction publication-title: Eur J Ophthalmol doi: 10.1177/1120672118817687 – volume: 103 start-page: 742 year: 2020 ident: R5-20250504 article-title: Non-pharmaceutical treatment options for meibomian gland dysfunction publication-title: Clin Exp Optom doi: 10.1111/cxo.13035 – volume: 52 start-page: 1938 year: 2011 ident: R26-20250504 article-title: The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.10-6997c – volume: 52 start-page: 1994 year: 2011 ident: R1-20250504 article-title: The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.10-6997e – volume: 101 start-page: 23 year: 2018 ident: R36-20250504 article-title: Intense pulsed light treatment and meibomian gland expression for moderate to advanced meibomian gland dysfunction publication-title: Clin Exp Optom doi: 10.1111/cxo.12541 – volume: 33 start-page: 41 year: 2015 ident: R35-20250504 article-title: Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction; a 3-year retrospective study publication-title: Photomed Laser Surg doi: 10.1089/pho.2014.3819 – volume: 66 start-page: 207 year: 2018 ident: R23-20250504 article-title: Prevalence and risk factors of dry eye disease in North India: ocular surface disease index-based cross-sectional hospital study publication-title: Indian J Ophthalmol doi: 10.4103/ijo.IJO_698_17 – volume: 9 start-page: e105575 year: 2014 ident: R12-20250504 article-title: Meibomian gland dysfunction determines the severity of the dry eye conditions in visual display terminal workers publication-title: PLoS One doi: 10.1371/journal.pone.0105575 – volume: 17 start-page: 104 year: 2019 ident: R22-20250504 article-title: Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction publication-title: Ocul Surf doi: 10.1016/j.jtos.2018.11.004 – volume: 52 start-page: 2006 year: 2011 ident: R6-20250504 article-title: The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.10-6997f – volume: 35 start-page: 318 year: 2016 ident: R10-20250504 article-title: Combination therapy of intense pulsed light therapy and meibomian gland expression (IPL/MGX) can improve dry eye symptoms and meibomian gland function in patients with refractory dry eye: a retrospective analysis publication-title: Cornea doi: 10.1097/ICO.0000000000000735 – volume: 9 start-page: 147 year: 2019 ident: R33-20250504 article-title: Ocular surface workup in patients with meibomian gland dysfunction treated with intense regulated pulsed light publication-title: Diagnostics (Basel) doi: 10.3390/diagnostics9040147 – volume: 11 start-page: 113 year: 2019 ident: R31-20250504 article-title: Intense pulsed light therapy in the treatment of meibomian gland dysfunction: current perspectives publication-title: Clin Optom (Auckl) doi: 10.2147/OPTO.S217639 – volume: 2016 start-page: 1910694 year: 2016 ident: R13-20250504 article-title: Evaluation of the safety and effectiveness of intense pulsed light in the treatment of meibomian gland dysfunction publication-title: J Ophthalmol doi: 10.1155/2016/1910694 – volume: 20 start-page: 111 year: 2020 ident: R18-20250504 article-title: Evaluation of the efficacy of optimal pulsed technology treatment in patients with cataract and Meibomian gland dysfunction in the perioperative period publication-title: BMC Ophthalmol doi: 10.1186/s12886-020-01357-5 – volume: 39 start-page: 634 year: 2020 ident: R2-20250504 article-title: Meibomian gland dysfunction in a hospital-based population in Central India publication-title: Cornea doi: 10.1097/ICO.0000000000002217 – volume: 34 start-page: 1193 year: 2015 ident: R29-20250504 article-title: Evaluation of optical coherence tomography meibography in patients with obstructive meibomian gland dysfunction publication-title: Cornea doi: 10.1097/ICO.0000000000000563 – volume: 99 start-page: 489 year: 2021 ident: R21-20250504 article-title: Therapeutic effects of acupuncture in typical dry eye: a systematic review and meta-analysis publication-title: Acta Ophthalmol doi: 10.1111/aos.14651 – volume: 40 start-page: 213 year: 2017 ident: R37-20250504 article-title: Meibomian gland dysfunction and its determinants in Iranian adults: a population-based study publication-title: Cont Lens Anterior Eye doi: 10.1016/j.clae.2017.05.003 – volume: 44 start-page: 06 year: 2018 ident: R14-20250504 article-title: Development of a meibomian gland dysfunction-specific symptom questionnaire publication-title: Eye Contact Lens doi: 10.1097/ICL.0000000000000294 |
SSID | ssj0013724 |
Score | 2.4160862 |
Snippet | To observe the clinical outcomes of intense pulsed light (IPL) for meibomian gland dysfunction (MGD) and identify its influencing factors.Forty-eight eyes of... To observe the clinical outcomes of intense pulsed light (IPL) for meibomian gland dysfunction (MGD) and identify its influencing factors. Forty-eight eyes of... |
SourceID | pubmedcentral proquest pubmed crossref wolterskluwer |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | e28166 |
SubjectTerms | Adolescent Adult Dry Eye Syndromes - therapy Female Fluoresceins Humans Intense Pulsed Light Therapy Male Meibomian Gland Dysfunction - therapy Meibomian Glands Observational Study Young Adult |
Title | Factors influencing the clinical outcomes of intense pulsed light for meibomian gland dysfunction |
URI | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00005792-202112100-00069 https://www.ncbi.nlm.nih.gov/pubmed/34889288 https://www.proquest.com/docview/2608541453 https://pubmed.ncbi.nlm.nih.gov/PMC8663838 |
Volume | 100 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZCmMwxu7LLkWDvWXqbFmypcetSSlj3Ri0o29GtmUalsaliSndr9-RdcmloazLgxMUWZFzPknnSOd8B6EPiqoqTktOUhlzwoqKElkWKalTlkVVEhu-FONt8T09PGFfT_lpr7fqtdQuir3yz9a4kv-RKpSBXE2U7B0kGxqFAvgM8oUrSBiu_yTjA5csZ-IyjfjQpxDu2LQL-F3HK9s5q-vhRQurYTWcGqu8czI815OiOTcDvcvnMayu52a1CxLz-Z7cKbzRSb-o6WJiXXTDRsK-i_Mw75tlo8mypGm7ab8l160v_Ob8gn86GnC3C0Fj49Hh_FF9VIChvrQZd_a0n0xTwqVlKQ-zbRStwMrSlbrJU1NziLl1Xrd8wUcjSzdpX6H2Oov2xuoWfA79afvRKN9s5B7aoWBl0D7a-fFrPB4tj6EyykLOX3g4T1sls09b-rKu2tywV2663T68aoxLxPx3FxGxotccP0aPnEGCP1t0PUE9PXuK7nthP0PKgQyvgAwDyLAHGfYgw02NHciwBRnuQIYBZDiADHcgwysge45ODsbH-4fE5eUgJQP9kggwkRmTqRaqTjLFa8EUqIFREUlRRrBgliJWnHKm60RTbYL74qw2eRWUrCXjyQvUnzUz_QphXaoqqVlcFgwsfZEoXZeglIOZDK2CdjVA1P-leelI603ulGl-izgH6GO46cJyttxe_b2XVQ5zqzkwUzPdtPMcbH3BoWMc-vHSyi40mMDKJ6kQA5StSTVUMLzt69_MJmcdf7sALV8kcCdZk39uI5-7_vFMUmLGmeH366gfUvn6bo_1Bj1YDtS3qL-4bPU7UKAXxW638bTrwP4X_sC9dQ |
linkProvider | Ovid |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9MwELagKwESQrwpTyOhnAgkjp3Yhx6qNqUs24LULrucIiexRcVuUpEWxL9nJo9CWYFELokU24oyE8_3ZV6EvNBM536YCTdUvnB5mjNXZWno2pBHXh74WC8Foy3m4fSYH56K0zbaAnNhMPusWr_CU71P4wX2w0FiuBwcLpx5fLIYFM5oMRp8cj4M38T1f2qMknDGg_Kb3TjDeR1_JSLFQAeA4ACrqbOnQ3WZHISCRV6PHLz_GMfjX_6GiPFdc1eA2F19IhW9no2bGofNwdDPtm_DLgDTi_GV17-X6PuuvtSh778ZsMlNcqNFnnTYqMotcskUt8mVWetbv0P0pGm9Q1dt3xIwahTgIe2SJ2m53cDLMhUtLV3Voe-GrrdgW3N6hhyfAgCm52aVluegdLTuDkLzHxXaTpT_XXI8iZejqds2YHAzDkDClcCFOFehkdoGkRZWcg323ks9JTMPdsZM-loAxTQ2MMxgFpcfWSygr5VVXAT3SK8oC_OAUJPpPLDcz1IOlE4G2tgM0BfwIVgVzGifsO6VJllbnRybZJwlnZd8Nk7-lEOfvNxNWjfFOf49_HknqwQ-IvSM6MKU2yoBUiexH7qA57jfyG63YABbnGJS9km0J9XdACzQvX-nWH2uC3VLgHMygJnunvyTJsU1-ZuWPvzP8c_I1elydpQcvZ2_e0Su4V0MuPG9x6S3-bo1TwA2bdKnrc7_BNkvCzs |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdGJ01ICI3vwgZGQnkiKB9OYj_kYWpSxqDdpG6wPUWOY4uKLalIC9p_z10-OsoQEnlppDhWlHN8v1_v7neEvJGeLNxQBXYo3MBmeeHZQuWhbUIWOYXvol4KZltMw8MzdnQenG-RPmKKxWf14h3-NNs0nmA7HOSFp_HRzBrNRvGFNU2_zOKpdXLwPm3-psYkCeskGcfXVhJXP8zSSo7jXp9xkrQihe3hYaDsDtnmPHTYgGwff07T5CbuEHls3eQVoHavU_T3aTZ92S2AejvP8t7PCmPg9bcmBf43RzbeJfc7BEoP2iXzgGzp8iHZmXQx9kdEjtsWPHTe9S8B50YBJtK-iJJWqyW8NV3TytB5kwKv6WIFPragl8j1KQBheqXneXUFi482XUJocV2jD8V18JicjdPT0aHdNWKwFQNAYXPgRIyJUHNp_EgGhjMJft_JHcGVAzuk4q4MgGpq42tPYzWXGxkU0pfCCBb4T8igrEr9jFCtZOEb5qqcAbXjvtRGAQoDXgSzgjsdEq9_pZnqVMqxWcZl1kfLJ0n2px2G5O36pkUr0vHv4a97W2XwMWGERJa6WtUZkDuOfdEDeI6nre3WE_qw1QmP8yGJNqy6HoBC3ZtXyvnXRrCbA6zjPtxpb9g_a0tdm-cLIuHBjgV0HDh4U-sfiuf_Of4V2YFvIPv0YfrxBbmLFzHvxnX2yGD5faX3AT0t85fdkv8FAasM0A |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Factors+influencing+the+clinical+outcomes+of+intense+pulsed+light+for+meibomian+gland+dysfunction&rft.jtitle=Medicine+%28Baltimore%29&rft.au=Chen%2C+Chen&rft.au=Chen%2C+Di&rft.au=Chou%2C+Yu-yu&rft.au=Long%2C+Qin&rft.date=2021-12-10&rft.issn=0025-7974&rft.eissn=1536-5964&rft.volume=100&rft.issue=49&rft.spage=e28166&rft_id=info:doi/10.1097%2FMD.0000000000028166&rft.externalDBID=n%2Fa&rft.externalDocID=10_1097_MD_0000000000028166 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0025-7974&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0025-7974&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0025-7974&client=summon |